Literature DB >> 16140553

Association of the mu-opioid receptor gene with type 2 diabetes mellitus in an African American population.

Carla J Gallagher1, Candace J Gordon, Carl D Langefeld, Josyf C Mychaleckyj, Barry I Freedman, Stephen S Rich, Donald W Bowden, Michèle M Sale.   

Abstract

African Americans (AA) are at increased risk for developing type 2 diabetes mellitus (T2DM) relative to European Americans. We previously detected linkage of T2DM to 6q24-q27 (LOD 2.26) at 163.5 cM, closest to marker D6S1035, in a genome-wide scan of AA families. The mu-opioid receptor gene (OPRM1) is located within the LOD-1 support interval of this linkage peak. OPRM1 is an attractive positional candidate gene for T2DM susceptibility since agonists of OPRM1 affect glucose-induced insulin release and OPRM1 knockout mice have a more rapid induction of insulin resistance than wild-type. Twenty-two SNPs in this gene, at an average spacing of 3.9 kb, were genotyped in 380 AA T2DM cases and 276 AA controls. In single SNP association analyses, rs648007 demonstrated significant evidence of association with T2DM (P=0.013). Four blocks of high linkage disequilibrium were detected across the OPRM1 gene. Association analyses of haplotypes in each of these blocks revealed two haplotype blocks with significant overall P values (P=0.007 and 0.046). Significant, but rare, risk and protective haplotypes were identified as driving these associations with T2DM (P=0.034-0.047). These associations suggest that the OPRM1 gene plays a role in T2DM susceptibility in African Americans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140553     DOI: 10.1016/j.ymgme.2005.07.013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

1.  Lower extremity vascular injuries: increased mortality for minorities and the uninsured?

Authors:  Marie Crandall; Douglas Sharp; Karen Brasel; Mercedes Carnethon; Adil Haider; Thomas Esposito
Journal:  Surgery       Date:  2011-10       Impact factor: 3.982

2.  Increased adiposity on normal diet, but decreased susceptibility to diet-induced obesity in mu-opioid receptor-deficient mice.

Authors:  Aamir R Zuberi; Leigh Townsend; Laurel Patterson; Huiyuan Zheng; Hans-Rudi Berthoud
Journal:  Eur J Pharmacol       Date:  2008-02-26       Impact factor: 4.432

3.  Evaluation of a SNP map of 6q24-27 confirms diabetic nephropathy loci and identifies novel associations in type 2 diabetes patients with nephropathy from an African-American population.

Authors:  Tennille S Leak; Josyf C Mychaleckyj; Shelly G Smith; Keith L Keene; Candace J Gordon; Pamela J Hicks; Barry I Freedman; Donald W Bowden; Michèle M Sale
Journal:  Hum Genet       Date:  2008-06-17       Impact factor: 4.132

4.  Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population.

Authors:  Tennille S Leak; Keith L Keene; Carl D Langefeld; Carla J Gallagher; Josyf C Mychaleckyj; Barry I Freedman; Donald W Bowden; Stephen S Rich; Michèle M Sale
Journal:  Mol Genet Metab       Date:  2007-07-06       Impact factor: 4.797

5.  Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.

Authors:  Jacobi I Cunningham; David J Eyerman; Mark S Todtenkopf; Reginald L Dean; Daniel R Deaver; Connie Sanchez; Mark Namchuk
Journal:  J Psychopharmacol       Date:  2019-07-11       Impact factor: 4.153

6.  Hepatic transcript signatures predict atherosclerotic lesion burden prior to a 2-year high cholesterol, high fat diet challenge.

Authors:  Sobha Puppala; Kimberly D Spradling-Reeves; Jeannie Chan; Shifra Birnbaum; Deborah E Newman; Anthony G Comuzzie; Michael C Mahaney; John L VandeBerg; Michael Olivier; Laura A Cox
Journal:  PLoS One       Date:  2022-08-04       Impact factor: 3.752

7.  Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.

Authors:  Lei Sun; Richard Mills; Brian M Sadler; Bhaskar Rege
Journal:  J Clin Pharmacol       Date:  2021-08-04       Impact factor: 3.126

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.